Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to “Strong-Buy”

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by research analysts at StockNews.com from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

A number of other research analysts also recently commented on ESPR. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

Esperion Therapeutics Stock Up 2.5 %

ESPR traded up $0.05 on Thursday, reaching $2.09. 7,461,575 shares of the company traded hands, compared to its average volume of 7,048,547. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The firm has a fifty day simple moving average of $2.30 and a two-hundred day simple moving average of $2.07. The company has a market cap of $395.85 million, a P/E ratio of -0.99 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same quarter in the previous year, the business earned ($0.76) EPS. On average, equities analysts forecast that Esperion Therapeutics will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Spire Wealth Management grew its position in shares of Esperion Therapeutics by 69.2% in the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 7,267 shares during the last quarter. Private Portfolio Partners LLC purchased a new stake in Esperion Therapeutics during the 4th quarter worth approximately $30,000. Herbst Group LLC purchased a new stake in Esperion Therapeutics during the 1st quarter worth approximately $28,000. Summit Financial LLC grew its position in Esperion Therapeutics by 66.8% during the 1st quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 10,355 shares during the last quarter. Finally, PSI Advisors LLC grew its position in Esperion Therapeutics by 161.5% during the 4th quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 10,500 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.